Skip to main content
. 2013 Aug 16;15(10):1429–1437. doi: 10.1093/neuonc/not114

Table 2.

Neurocognitive evaluation completion

Baseline 8 Weeks 16 Weeks 24 Weeks 52 Weeks
Clinically eligible patients 508 508 508 508 508
Withdrawn consent (entire protocol) 9 (2%) 43 (8%) 53 (10%) 55 (11%) 55 (11%)
Inevaluable, patient death 2 (0.4%) 14 (3%) 109 (21%) 173 (34%) 271 (53%)
Evaluable patients 497 451 346 280 182
Analyzable 470 (95%) 266 (59%) 179 (52%) 149 (53%) 79 (43%)
Not analyzable 27 (5%) 185 (41%) 167 (48%) 131 (47%) 103 (57%)